Simple hysterectomy with pelvic node dissection is a safe treatment option for people with early-stage, low-risk cervical cancer and may help improve quality of life, according to results from a large, international phase III clinical trial. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 2, 2023
May 25, 2023
Adding the immunotherapy drug pembrolizumab (Keytruda®) to chemotherapy, with or without bevacizumab (Avastin®), improved overall survival (OS) and progression-free survival (PFS) in people with persistent, recurrent, or metastatic cervical cancer, regardless of whether the cancer expressed PD-L1. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
May 25, 2023
Patients with breast cancer in the overweight or obese body mass index (BMI) ranges can achieve meaningful weight loss through a telephone-based intervention. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
May 25, 2023
Medicaid Expansion Linked to Decrease in Mortality and Racial Disparities for People With GI Cancers
Two-year mortality and racial disparities in survival among patients with gastrointestinal (GI) cancers decreased in the time following Medicaid expansion in 2014. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
May 25, 2023
Five-year overall survival improved by 30% for children with acute lymphoblastic leukemia (ALL) who were treated at the Hospital General-Tijuana in Mexico, after implementation of a cross-border cancer treatment training and access program facilitated in partnership with Rady Children’s Hospital-San Diego and St. Jude Children’s Research Hospital. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting and is in press with JCO Global Oncology for publication on Saturday, June 3.
May 25, 2023
Minimally invasive distal pancreatectomy with splenectomy is a safe and effective alternative to traditional open surgery for patients with resectable pancreatic cancer, according to results from DIPLOMA, an international randomized trial. This surgical approach, which removes tumors located on the body or the tail of the pancreas and the spleen, uses smaller incisions and offers a lower risk of serious complications compared to open surgery. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
May 9, 2023
Oncology professionals from around the world will convene in Chicago to discuss the latest clinical cancer research impacting patient care at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Optimizing care for patients, improving access to cancer care, and developing novel treatments are among the topics that will be highlighted in the meeting’s official Press Program.
April 19, 2023
Adding toripalimab to perioperative chemotherapy led to an improvement in event-free survival for patients with stage III resectable non-small cell lung cancer (NSCLC), according to research that will be presented during the April 2023 session of the American Society of Clinical Oncology (ASCO) Plenary Series.
April 19, 2023
In patients with KRASG12C mutated cancers, adagrasib, an oral drug that targets KRASG12C, may be an effective treatment, according to research that will be presented during the April 2023 session of the American Society of Clinical Oncology (ASCO) Plenary Series.
March 21, 2023
Zolbetuximab in combination with chemotherapy extends survival in patients with 1L claudin-18.2+ (CLDN18.2+)/HER2− locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. These results will be presented during the March 2023 session of the American Society of Clinical Oncology (ASCO) Plenary Series.
February 18, 2023
Eight notable studies exploring new approaches in the treatment and management of genitourinary cancers will be presented at the 2023 ASCO Genitourinary Cancers Symposium, taking place February 16-18, 2023, at the Moscone West Building in San Francisco, California.
February 18, 2023
Eight notable studies exploring new approaches in the treatment and management of genitourinary cancers will be presented at the 2023 ASCO Genitourinary Cancers Symposium, taking place February 16-18, 2023, at the Moscone West Building in San Francisco, California.
February 16, 2023
Polymerase Inhibitor Significantly Improves Progression-Free Survival for Metastatic Prostate Cancer
The TALAPRO-2 phase III clinical trial found that a polymerase inhibitor combined with an androgen receptor inhibitor had significantly better progression-free survival (PFS) versus the current standard of care for people with metastatic, castration-resistant prostate cancer (mCRPC), regardless of homologous recombination repair pathway status. Homologous recombination repair involves a pathway that can help fix DNA double-strand breaks and cross-links between DNA strands.
February 14, 2023
In patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL), ponatinib was more effective than imatinib when given with reduced-intensity chemotherapy. These results will be presented during the February 2023 session of the American Society of Clinical Oncology (ASCO) Plenary Series.
February 13, 2023
Study participants with prostate cancer who reported the highest amounts of plant-based foods in their diets had a 52% lower risk of the cancer progressing and a 53% lower risk of recurrence compared to those who had the lowest amounts of plants in their diets. The diet assessments were based on questionnaires of food consumption given to people enrolled in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) study.
Pages |